bexagliflozin CAS 1118567-05-7

• Iden­ti­fi­ca­tion
• Prop­er­ties
• Safe­ty Data
• Spec­i­fi­ca­tions & Oth­er Information
• Links
• Quick Inquiry

Iden­ti­fi­ca­tion

CAS Number

1118567-05-7

Name

bexagliflozin

Syn­onyms

(1S)-1,5-Anhydro-1-(4-chlor-3-{4-[2-(cyclopropyloxy)ethoxy]benzyl}phenyl)-D-glucitol [Ger­man] [ACD/IUPAC Name]
(1S)-1,5-Anhydro-1-(4-chloro-3-{4-[2-(cyclopropyloxy)ethoxy]benzyl}phenyl)-D-glucitol [ACD/IUPAC Name]
(1S)-1,5-Anhydro-1-(4-chloro-3-{4-[2-(cyclopropyloxy)éthoxy]benzyl}phényl)-D-glucitol [French] [ACD/IUPAC Name]
1118567-05-7 [RN]
bexagliflozin [INN] [USAN]
bexaglifloz­i­na [Span­ish] [INN]
bexagliflozine [French] [INN]
bexaglifloz­inum [Latin] [INN]
D-Glu­­ci­­tol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-, (1S)- [ACD/​Index Name]
EGT0001442
Egt-1442
EGT1442
THR1442
THR-1442
Бексаглифлозин [Russ­ian] [INN]
بيكساغليفلوزين [Ara­bic] [INN]
贝沙格列净 [Chi­nese] [INN]
(1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-D-glucitol
(2S,3R,4R,5S,6R)-2-(4-chloro-3-{[4-(2-cyclopropoxyethoxy)phenyl]methyl}phenyl)-6-(hydroxymethyl)oxane-3,4,5-triol
bexaglifloz­i­na
bexagliflozine
bexaglifloz­inum
Bexgliflozin (EGT1442)
MFCD22628819
MFCD28100944
бексаглифлозин
بيكساغليفلوزين
贝沙格列净

SMILES

c1cc(ccc1Cc2cc(ccc2Cl)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)OCCOC4CC4

Std­InChI

InChI=1S/C24H29ClO7/c25-19-8-3-15(24-23(29)22(28)21(27)20(13-26)32-24)12-16(19)11-14-1-4-17(5-2-14)30-9-10-31-18-6-7-18/h1-5,8,12,18,20-24,26-29H,6-7,9-11,13H2/t20-,21-,22+,23-,24+/m1/s1

Std­InChIKey

BTCRKOKVYTVOLU-SJS­RKZJXSA-N

Mol­e­c­u­lar Formula

C₂₄H₂₉ClO₇

Mol­e­c­u­lar Weight

464.936

MDL Number

MFCD28100944

Prop­er­ties

Safe­ty Data

Sym­bol

GHS07

Sig­nal Word

Warn­ing

Haz­ard statements

Pre­cau­tion­ary Statements

WGK Germany

3

MSDS Download

Spec­i­fi­ca­tions and Oth­er Infor­ma­tion of Our 

Known Appli­ca­tion

Bexagliflozin is a GLT2 inhibitor and a new type of hypo­glycemic drug. It can inhib­it SGLT2 in renal tubu­lar epithe­lial cells, lead­ing to an increase in the body’s caloric con­sump­tion, reduc­ing flu­id reten­tion and increas­ing uri­nary glu­cose excre­tion. SGLT2 inhibitors have obvi­ous advan­tages over oth­er drugs : (1) they can reduce pre- and post-meal blood glu­cose lev­els (not all drugs can reduce both at the same time); (2) because they do not stim­u­late insulin secre­tion, all The risk of hypo­glycemia for users is rel­a­tive­ly low ; (3) Due to its main effect on renal tubules, it pro­duces a diuret­ic effect, there­by reduc­ing sys­tolic blood pres­sure ; (4) Stud­ies have found that SGLT2 inhibitors have a ther­a­peu­tic effect on dia­bet­ic nephropathy.

In short, SGLT2 inhibitors have the func­tions of low­er­ing blood sug­ar, weight loss, and low­er­ing blood pres­sure, and have clear car­dio­vas­cu­lar and renal pro­tec­tive effects.

Gen­er­al View of Documents

Links

This prod­uct is devel­oped by our R&D com­pa­ny Cam­ing Phar­ma­ceu­ti­cal Lim­it­ed (http://​www​.cam​ing​.com/).

Quick Inquiry

Fill out our inquiry form and one of our experts will be in touch with you shortly.